Revvity
David McClymont is an accomplished professional in the field of automation and biotechnology, currently serving as the Head of Automation at Revvity since May 2023. Previously, David held the same role at Horizon Discovery from February 2019 to May 2023, where responsibilities included designing and developing gene editing manufacturing and screening platforms while leading cross-functional global project teams. At The London DNA Foundry, part of Imperial College, David managed robotic workcell automation and software development from December 2015 to February 2019. Prior experiences include serving as Head Engineer at the Biotechnology Centre Oslo, focusing on assay development and robotic automation, and as a Scientist at Xention Discovery specializing in assay development and automated electrophysiology. David earned a PhD in Molecular Pharmacology from the University of Nottingham between 2007 and 2011.
This person is not in any teams
This person is not in any offices
Revvity
9 followers
At Revvity, “impossible” is inspiration, and ""can't be done"" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. With more than $3 billion in revenue and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries. Learn more at www.revvity.com